RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+5.31%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$2.63B
AUM Growth
+$2.63B
(-15%)
Cap. Flow
-$276M
Cap. Flow
% of AUM
-10.5%
Top 10 Holdings %
Top 10 Hldgs %
36.37%
Holding
119
New
10
Increased
38
Reduced
30
Closed
12
Top Buys
| 1 |
Scholar Rock
SRRK
|
$31M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$28.6M |
| 3 |
Tenet Healthcare
THC
|
$16.3M |
| 4 |
Amicus Therapeutics
FOLD
|
$12.7M |
| 5 |
Janux Therapeutics
JANX
|
$10.9M |
Top Sells
| 1 |
UnitedHealth
UNH
|
$59.8M |
| 2 |
Humana
HUM
|
$46.9M |
| 3 |
Exact Sciences
EXAS
|
$39.2M |
| 4 |
Neurocrine Biosciences
NBIX
|
$29.8M |
| 5 |
Align Technology
ALGN
|
$29.1M |
Sector Composition
| 1 | Healthcare | 97.94% |
| 2 | Consumer Staples | 1.85% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
iRhythm Technologies
IRTC
$5.67B
| $35.8M | 1.36% |
397,500
| – | – |
|
27
Zai Lab
ZLAB
$3.48B
| $34.2M | 1.3% |
1,305,337
-10,336
| -0.8% | -$271K |
|
28
Nuvalent
NUVL
$5.74B
| $33.7M | 1.28% |
429,994
| – | – |
|
|
MREO
29
Mereo BioPharma
MREO
$275M
| $33.6M | 1.28% |
9,599,170
+65,000
| +0.7% | +$228K |
|
|
30
Scholar Rock
SRRK
$3.3B
| $31M | 1.18% |
+716,782
| New | +$31M |
|
31
Celldex Therapeutics
CLDX
$1.57B
| $30.9M | 1.18% |
1,222,182
+118,404
| +11% | +$2.99M |
|
32
Insulet
PODD
$24.2B
| $29.8M | 1.14% |
114,250
-19,750
| -15% | -$5.16M |
|
33
Structure Therapeutics
GPCR
$1.14B
| $29.3M | 1.12% |
1,080,963
+17,053
| +2% | +$462K |
|
34
DexCom
DXCM
$30.9B
| $27.5M | 1.05% |
353,000
-171,000
| -33% | -$13.3M |
|
35
Akero Therapeutics
AKRO
$3.65B
| $26.3M | 1% |
946,499
+13,100
| +1% | +$364K |
|
|
36
Exact Sciences
EXAS
$9.33B
| $25.3M | 0.96% |
450,000
-697,500
| -61% | -$39.2M |
|
|
37
Amicus Therapeutics
FOLD
$2.42B
| $24.5M | 0.93% |
2,599,425
+1,349,145
| +108% | +$12.7M |
|
38
Inspire Medical Systems
INSP
$2.53B
| $24.1M | 0.92% |
130,000
| – | – |
|
39
Azenta
AZTA
$1.35B
| $23.8M | 0.9% |
475,000
-57,500
| -11% | -$2.88M |
|
40
Evolent Health
EVH
$1.11B
| $23.2M | 0.88% |
2,060,000
-10,000
| -0.5% | -$113K |
|
41
Acadia Healthcare
ACHC
$2.15B
| $23.1M | 0.88% |
583,500
-231,500
| -28% | -$9.18M |
|
42
Immunovant
IMVT
$2.91B
| $22.5M | 0.86% |
909,103
-312,206
| -26% | -$7.73M |
|
43
Warby Parker
WRBY
$3.08B
| $22.3M | 0.85% |
920,000
-519,050
| -36% | -$12.6M |
|
44
Vera Therapeutics
VERA
$1.47B
| $20.6M | 0.79% |
487,863
+104,371
| +27% | +$4.41M |
|
45
BioCryst Pharmaceuticals
BCRX
$1.74B
| $20.1M | 0.77% |
2,677,996
-944,362
| -26% | -$7.1M |
|
46
NewAmsterdam Pharma
NAMS
$2.8B
| $19.7M | 0.75% |
767,522
+414,203
| +117% | +$10.6M |
|
47
Summit Therapeutics
SMMT
$17.5B
| $18.8M | 0.72% |
1,054,000
+14,000
| +1% | +$250K |
|
48
Lifestance Health
LFST
$2.14B
| $18.8M | 0.72% |
2,550,000
-551,000
| -18% | -$4.06M |
|
49
Legend Biotech
LEGN
$6.64B
| $16.7M | 0.63% |
512,132
+3,200
| +0.6% | +$104K |
|
|
50
Tenet Healthcare
THC
$16.5B
| $16.3M | 0.62% |
+129,200
| New | +$16.3M |
|